As of May 4, 2025, Bluejay Diagnostics's market capitalization has reached $1.06 M. According to our data, Bluejay Diagnostics is the 46670th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
Bluejay Diagnostics has seen its market value drop from $49.91 M to $1.06 M since 2021, representing a total decrease of 97.87% and an annual compound decline rate (CAGR) of 68.46%.
Date
Market Cap
Change (%)
May 2, 2025
$1.06 M
-59.38%
December 31, 2024
$2.62 M
73.26%
December 29, 2023
$1.51 M
-80.26%
December 30, 2022
$7.66 M
-84.66%
December 31, 2021
$49.91 M
Company Profile
Bluejay Diagnostics was founded in 2015 in United States.
The company went public on November 10, 2021
on the Nasdaq Stock Market.
With 7 employees, it focuses on Healthcare and aims to drive innovation in Medical Devices.
Frequently Asked Questions
As of May 4, 2025, Bluejay Diagnostics (including the parent company, if applicable) has an estimated market capitalization of $1.06 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
Bluejay Diagnostics global market capitalization ranking is approximately 46670 as of May 4, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.